AKEBIA THERAPEUTICS, INC. SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense
AKEBIA THERAPEUTICS, INC. (AKBA) reported SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense of $40.22 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Valuation and Qualifying Accounts
us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense · last filed 2026-08-05
- AKEBIA THERAPEUTICS, INC. sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for the quarter ending 2026-06-30 was $18.33M, a 20.67% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for the quarter ending 2026-03-31 was $21.89M, a 4.65% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for the quarter ending 2025-12-31 was $20.38M, a 2.75% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for the quarter ending 2025-09-30 was $21.30M, a 67.11% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for fiscal 2025 was $85.70M, a 45.26% increase from fiscal 2024.
- AKEBIA THERAPEUTICS, INC. sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for fiscal 2024 was $59.00M, a 39.15% decline from fiscal 2023.
- AKEBIA THERAPEUTICS, INC. sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for fiscal 2023 was $96.97M, a 8.62% decline from fiscal 2022.
- AKEBIA THERAPEUTICS, INC. sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for fiscal 2022 was $106.11M, a 29.30% decline from fiscal 2021.
| Period end | SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense 1 month | SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense 3 month | SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense 3 month as first filed | SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense 6 month | SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense 6 month as first filed | SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense 9 month | SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense 9 month as first filed | SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense 12 month | SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $18.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $40.22M 10-Q · filed 2026-08-05 | $60.60M derived: sum of 3 quarters · filed 2026-08-05 | $81.90M derived: sum of 4 quarters · filed 2026-08-05 | |||||
| 2026-03-31 | $21.89M 10-Q · filed 2026-05-07 | $42.27M derived: sum of 2 quarters · filed 2026-05-07 | $63.57M derived: sum of 3 quarters · filed 2026-05-07 | $86.68M derived: sum of 4 quarters · filed 2026-08-05 | |||||
| 2025-12-31 | $20.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $41.68M derived: sum of 2 quarters · filed 2026-02-26 | $64.79M derived: sum of 3 quarters · filed 2026-08-05 | $85.70M 10-K · filed 2026-02-26 | |||||
| 2025-09-30 | $21.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $44.41M derived: sum of 2 quarters · filed 2026-08-05 | $65.32M 10-Q · filed 2025-11-10 | $86.28M derived: sum of 4 quarters · filed 2026-08-05 | |||||
| 2025-06-30 | $23.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $44.02M 10-Q · filed 2026-08-05 | $64.98M derived: sum of 3 quarters · filed 2026-08-05 | $77.72M derived: sum of 4 quarters · filed 2026-08-05 | |||||
| 2025-03-31 | $20.91M 10-Q · filed 2026-05-07 | $41.87M derived: sum of 2 quarters · filed 2026-05-07 | $54.62M derived: sum of 3 quarters · filed 2026-05-07 | $66.81M derived: sum of 4 quarters · filed 2026-05-07 | |||||
| 2024-12-31 | $20.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $33.70M derived: sum of 2 quarters · filed 2026-02-26 | $45.90M derived: sum of 3 quarters · filed 2026-02-26 | $59.00M 10-K · filed 2026-02-26 | |||||
| 2024-09-30 | $12.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $24.94M derived: sum of 2 quarters · filed 2025-11-10 | $38.04M 10-Q · filed 2025-11-10 | $65.19M derived: sum of 4 quarters · filed 2026-02-26 | |||||
| 2024-06-30 | $12.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $25.30M 10-Q · filed 2025-08-07 | $52.44M derived: sum of 3 quarters · filed 2026-02-26 | $75.48M derived: sum of 4 quarters · filed 2026-02-26 | |||||
| 2024-03-31 | $13.10M 10-Q · filed 2025-05-08 | $40.24M derived: sum of 2 quarters · filed 2026-02-26 | $63.29M derived: sum of 3 quarters · filed 2026-02-26 | $89.58M derived: sum of 4 quarters · filed 2026-02-26 | |||||
| 2023-12-31 | $27.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $50.19M derived: sum of 2 quarters · filed 2026-02-26 | $76.48M derived: sum of 3 quarters · filed 2026-02-26 | $96.97M 10-K · filed 2026-02-26 | |||||
| 2023-09-30 | $23.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $49.33M derived: sum of 2 quarters · filed 2024-11-07 | $69.82M 10-Q · filed 2024-11-07 | $99.39M derived: sum of 4 quarters · filed 2024-11-07 | |||||
| 2023-06-30 | $26.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $46.78M 10-Q · filed 2024-08-08 | $44.95M 10-Q · filed 2023-08-28 | $76.35M derived: sum of 3 quarters · filed 2024-08-08 | $102.63M derived: sum of 4 quarters · filed 2024-08-08 | ||||
| 2023-03-31 | $20.49M 10-Q · filed 2024-05-09 | $20.15M 10-Q · filed 2023-05-08 | $50.06M derived: sum of 2 quarters · filed 2024-05-09 | $76.34M derived: sum of 3 quarters · filed 2024-05-09 | $101.20M derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | $29.57M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $55.85M derived: sum of 2 quarters · filed 2024-03-14 | $80.72M derived: sum of 3 quarters · filed 2024-03-14 | $106.11M 10-K · filed 2024-03-14 | $106.22M 10-K · filed 2023-03-10 | ||||
| 2022-09-30 | $26.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $51.14M derived: sum of 2 quarters · filed 2023-11-08 | $76.54M 10-Q · filed 2023-11-08 | $76.61M 10-Q · filed 2022-11-03 | $107.42M derived: sum of 4 quarters · filed 2023-11-08 | ||||
| 2022-06-30 | $24.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-28 | $50.26M 10-Q · filed 2023-08-28 | $50.37M 10-Q · filed 2022-08-04 | $81.15M derived: sum of 3 quarters · filed 2023-08-28 | $121.49M derived: sum of 4 quarters · filed 2023-08-28 | ||||
| 2022-03-31 | $25.39M 10-Q · filed 2023-05-08 | $56.28M derived: sum of 2 quarters · filed 2023-08-28 | $96.63M derived: sum of 3 quarters · filed 2023-08-28 | $136.52M derived: sum of 4 quarters · filed 2023-08-28 | |||||
| 2021-12-31 | $30.89M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-08-28 | $71.23M derived: sum of 2 quarters · filed 2023-08-28 | $111.13M derived: sum of 3 quarters · filed 2023-08-28 | $150.09M 10-K/A · filed 2023-08-28 | $150.91M 10-K · filed 2022-03-01 | ||||
| 2021-09-30 | $40.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $80.24M derived: sum of 2 quarters · filed 2022-11-03 | $119.21M 10-Q · filed 2022-11-03 | $170.43M derived: sum of 4 quarters · filed 2023-08-28 | |||||
| 2021-06-30 | $39.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $78.86M 10-Q · filed 2022-08-04 | $130.09M derived: sum of 3 quarters · filed 2023-08-28 | $175.44M derived: sum of 4 quarters · filed 2023-08-28 | |||||
| 2021-03-31 | $38.97M 10-Q · filed 2022-05-09 | $90.19M derived: sum of 2 quarters · filed 2023-08-28 | $135.54M derived: sum of 3 quarters · filed 2023-08-28 | $175.80M derived: sum of 4 quarters · filed 2023-08-28 | |||||
| 2020-12-31 | $51.22M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-08-28 | $96.57M derived: sum of 2 quarters · filed 2023-08-28 | $136.84M derived: sum of 3 quarters · filed 2023-08-28 | $170.66M 10-K/A · filed 2023-08-28 | $167.27M 10-K · filed 2021-02-25 | ||||
| 2020-09-30 | $45.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $85.62M derived: sum of 2 quarters · filed 2021-11-04 | $119.44M 10-Q · filed 2021-11-04 | $159.26M derived: sum of 4 quarters · filed 2022-03-01 | |||||
| 2020-06-30 | $40.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $74.09M 10-Q · filed 2021-08-05 | $113.91M derived: sum of 3 quarters · filed 2022-03-01 | $145.17M derived: sum of 4 quarters · filed 2022-03-01 | |||||
| 2020-03-31 | $33.82M 10-Q · filed 2021-05-10 | $73.64M derived: sum of 2 quarters · filed 2022-03-01 | $104.91M derived: sum of 3 quarters · filed 2022-03-01 | $134.69M derived: sum of 4 quarters · filed 2022-03-01 | |||||
| 2019-12-31 | $39.82M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $71.09M derived: sum of 2 quarters · filed 2022-03-01 | $100.86M derived: sum of 3 quarters · filed 2022-03-01 | $120.70M 10-K · filed 2022-03-01 | |||||
| 2019-09-30 | $31.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $61.04M derived: sum of 2 quarters · filed 2020-11-05 | $80.88M 10-Q · filed 2020-11-05 | ||||||
| 2019-06-30 | $29.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $49.61M 10-Q · filed 2020-08-10 | |||||||
| 2019-03-31 | $19.83M 10-Q · filed 2020-05-05 | ||||||||
| 2018-12-31 | $4.23M 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |